Nyxoah SA (NYXH)
NASDAQ: NYXH · Real-Time Price · USD
2.823
-0.097 (-3.32%)
May 19, 2026, 11:31 AM EDT - Market open
Company Description
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea.
Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA
| Country | Belgium |
| Founded | 2009 |
| IPO Date | Jul 2, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 154 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 1 045 90 75 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $30.00 |
| CIK Code | 1857190 |
| ISIN Number | BE0974358906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olivier Taelman | Chief Executive Officer and Executive Director |
| Robert Taub MBA | Co-Founder and Chairman |
| Bruno Onkelinx | Chief Technical Officer |
| John Landry | Chief Financial Officer |
| Jeyakumar Subbaroyan | Chief Science Officer |
| Pearson Dennis | Investor Relations Associate |
| An Moonen | General Counsel |
| Geeta Kaveti | Chief Compliance Officer |
| Maggie McGowan | Chief Human Resources Officer |
| Loic Moreau | President of International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2026 | 6-K | Report of foreign issuer |
| Mar 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 19, 2026 | 6-K | Report of foreign issuer |
| Jan 30, 2026 | 6-K | Report of foreign issuer |
| Jan 14, 2026 | 6-K | Report of foreign issuer |
| Dec 29, 2025 | SCHEDULE 13G | Filing |
| Dec 19, 2025 | 6-K | Report of foreign issuer |
| Dec 5, 2025 | 6-K | Report of foreign issuer |
| Nov 24, 2025 | SCHEDULE 13D/A | Filing |